(0.06%) 5 472.58 points
(0.09%) 39 149 points
(0.37%) 17 783 points
(-0.22%) $80.65
(-3.66%) $2.66
(-0.76%) $2 313.20
(0.23%) $28.94
(3.58%) $1 021.70
(0.28%) $0.936
(0.70%) $10.68
(0.46%) $0.792
(-0.28%) $87.25
Live Chart Being Loaded With Signals
Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States...
Stats | |
---|---|
今日成交量 | 21 |
平均成交量 | 7 453 |
市值 | 67.15M |
EPS | $-0.190 ( Q3 | 2024-03-15 ) |
下一个收益日期 | ( $-0.160 ) 2024-07-22 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-6.86 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0 (0.00%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-10-09 | Davis Brady | Buy | 68 000 | Option to purchase Common Stock |
2023-10-09 | Davis Brady | Buy | 7 500 | Option to purchase Common Stock |
2023-10-09 | Davis Brady | Buy | 135 000 | Option to purchase Common Stock |
2024-01-12 | Mendelson Daniel Newman | Buy | 1 000 | Common Stock |
2024-01-11 | Mendelson Daniel Newman | Buy | 2 000 | Common Stock |
INSIDER POWER |
---|
90.14 |
Last 100 transactions |
Buy: 1 237 465 | Sell: 480 213 |
Champions Oncology Inc 财务报表
Annual | 2023 |
营收: | $53.87M |
毛利润: | $24.34M (45.18 %) |
EPS: | $-0.390 |
FY | 2023 |
营收: | $53.87M |
毛利润: | $24.34M (45.18 %) |
EPS: | $-0.390 |
FY | 2022 |
营收: | $49.11M |
毛利润: | $25.48M (51.88 %) |
EPS: | $0.0415 |
FY | 2021 |
营收: | $41.04M |
毛利润: | $19.59M (47.74 %) |
EPS: | $0.0300 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Champions Oncology Inc
Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Technology Platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. The company provides Lumin Bioinformatics, a software platform and data tool that contains comprehensive information derived from research services and clinical studies, and sold on an annual subscriptions basis. The company markets its products through internet, word of mouth, and sales force to patients and physicians. The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。